Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -24.35%435M | -8.97%193.42M | 141.06%163.35M | -31.65%94.83M | -110.64%-16.6M | -7.11%575M | -22.48%212.48M | 67.77M | 138.74M | 36.86%156.02M |
Net income from continuing operations | 102.95%619M | 492.29%150.56M | 70.51%124.74M | -41.61%82.4M | 102.39%261.3M | -33.26%305M | -123.09%-38.38M | --73.16M | --141.11M | 36.95%129.11M |
Operating gains losses | 22.56%-103M | 40.87%-38.97M | -1,221.50%-49.12M | 190.43%32.15M | -69.09%-47.06M | 17.39%-133M | -9.19%-65.9M | ---3.72M | ---35.55M | -28.92%-27.83M |
Depreciation and amortization | 28.09%342M | -14.20%103.56M | 125.97%93.5M | 55.21%78.25M | 22.34%66.68M | 25.94%267M | 48.24%120.7M | --41.38M | --50.42M | 12.48%54.51M |
Deferred tax | -138.05%-121M | -102.05%-5.31M | -43.63%17.38M | -66.93%10.17M | -4,546.53%-143.25M | 156.45%318M | 193.04%259.5M | --30.84M | --30.75M | 3.43%-3.08M |
Other non cash items | -46.95%148M | -55.01%50.34M | -4.36%34.48M | -60.73%28.75M | -40.48%34.43M | 35.44%279M | 23.65%111.89M | --36.06M | --73.21M | 29.49%57.85M |
Change In working capital | -154.55%-336M | 274.98%32.69M | 37.79%-45.08M | -312.63%-132.89M | -2,103.92%-190.73M | 0.00%-132M | -187.78%-18.68M | ---72.46M | ---32.21M | 82.83%-8.65M |
-Change in receivables | -172.19%-411M | 165.29%37.78M | 44.03%-42.97M | -909.23%-110.82M | -882.08%-294.99M | 35.19%-151M | 18.61%-57.87M | ---76.79M | --13.69M | -62.96%-30.04M |
-Change in inventory | 42.86%-20M | 93.14%10.52M | 82.16%-3.73M | -495.97%-8.68M | 16.66%-18.11M | -66.67%-35M | 231.88%5.45M | ---20.91M | --2.19M | 21.20%-21.73M |
-Change in payables and accrued expense | 82.81%117M | -94.70%2.26M | -79.87%3.74M | 70.65%-12.48M | 172.97%123.48M | -49.21%64M | -55.94%42.73M | --18.56M | ---42.52M | 1,648.27%45.24M |
-Change in other working capital | -120.00%-22M | -98.86%-17.87M | -153.11%-1.94M | 57.80%-1.08M | 47.72%-1.11M | -150.00%-10M | -1,836.16%-8.99M | --3.66M | ---2.55M | -45.39%-2.12M |
Cash from discontinued investing activities | 0 | |||||||||
Operating cash flow | -24.35%435M | -8.97%193.42M | 141.06%163.35M | -31.65%94.83M | -110.64%-16.6M | -7.11%575M | -22.48%212.48M | --67.77M | --138.74M | 36.86%156.02M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 22.87%-344M | 27.42%-88.01M | 10.75%-74.91M | -114.10%-142.58M | 77.90%-38.49M | 22.43%-446M | 50.29%-121.27M | -83.93M | -66.6M | -141.26%-174.2M |
Net PPE purchase and sale | 40.95%-447M | 64.76%-137.09M | 20.98%-59.97M | 5.75%-117.09M | 20.84%-132.85M | -81.97%-757M | -146.45%-389.06M | ---75.89M | ---124.24M | -137.22%-167.82M |
Net intangibles purchase and sale | --0 | -99.65%53.85K | 256.27%2.64M | -86.23%-2.7M | --0 | 300.00%20M | 521.32%15.35M | ---1.69M | ---1.45M | 241.70%7.8M |
Net business purchase and sale | 52.11%108M | -2.30%33.98M | 47.43%45.26M | 78.47%9.39M | 7,246.00%19.37M | 205.97%71M | 134.89%34.78M | --30.7M | --5.26M | -81.01%263.7K |
Net investment purchase and sale | -106.64%-15M | -93.95%13.29M | -88.36%-63.58M | -158.88%-31.58M | 598.79%66.86M | 319.42%226M | 1,275.39%219.53M | ---33.75M | --53.63M | 32.03%-13.41M |
Net other investing changes | 116.67%1M | 160.32%1.12M | 100.22%7.21K | ---- | ---- | -154.55%-6M | -161.21%-1.86M | ---3.3M | --193.39K | -109.84%-1.04M |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 22.87%-344M | 27.42%-88.01M | 10.75%-74.91M | -114.10%-142.58M | 77.90%-38.49M | 22.43%-446M | 50.29%-121.27M | ---83.93M | ---66.6M | -141.26%-174.2M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 935.09%476M | 420.31%317.6M | 1,738.50%85.56M | -134.17%-5.37M | 147.09%78.21M | -23.91%-57M | -282.63%-99.15M | -5.22M | 15.72M | 264.87%31.65M |
Net issuance payments of debt | 177.23%621M | 977.47%354.8M | 322.77%114.94M | -60.48%33.2M | 47.83%118.06M | 67.16%224M | -37.41%32.93M | --27.19M | --84.02M | 271.95%79.86M |
Net common stock issuance | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Cash dividends paid | --0 | 106.36%38.32K | -98.40%2.32K | 92.51%-40.64K | --0 | ---1M | -395.17%-602.12K | --144.68K | ---542.56K | --0 |
Cash from discontinued financing activities | 0 | |||||||||
Financing cash flow | 935.09%476M | 420.31%317.6M | 1,738.50%85.56M | -134.17%-5.37M | 147.09%78.21M | -23.91%-57M | -282.63%-99.15M | ---5.22M | --15.72M | 264.87%31.65M |
Net cash flow | ||||||||||
Beginning cash position | 61.32%171M | 81.70%333.48M | -23.20%152.13M | 58.88%200.33M | 79.13%161.09M | -3.64%106M | 89.29%183.53M | --198.09M | --126.09M | -11.61%89.93M |
Current changes in cash | 687.50%567M | 5,423.92%423M | 913.56%174M | -160.47%-53.13M | 71.65%23.13M | 3,700.00%72M | -287.59%-7.95M | ---21.39M | --87.86M | -40.38%13.47M |
Effect of exchange rate changes | --0 | 18.11%-46.59M | 122.19%15.99M | -27.61%14.49M | -28.98%16.11M | -250.00%-7M | -99.83%-56.9M | --7.2M | --20.02M | 201.24%22.68M |
End cash Position | 331.58%738M | 331.58%738M | 81.70%333.48M | -23.20%152.13M | 58.88%200.33M | 61.32%171M | 61.32%171M | --183.53M | --198.09M | -4.39%126.09M |
Free cash flow | 93.44%-12M | 131.98%56.72M | 1,404.00%105.69M | -271.75%-24.97M | -1,137.88%-149.44M | -206.40%-183M | -264.03%-177.36M | ---8.1M | --14.54M | -127.93%-12.07M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |